For the latest updates on our ongoing response to COVID-19, please click here.

Advancing Global Health 

Gilead recognizes that the development of innovative medicines for life-threatening diseases is only one aspect of improving public health. We also invest in programs that promote prevention, strengthen healthcare infrastructure, and provide education and social and financial support to the most vulnerable communities around the world.

By enabling access to medicines, challenging assumptions, fighting stigma and collaborating with partners worldwide, we work not simply to treat some of the world’s most challenging public health threats – but to eliminate them.

Expanding Treatment Access

Expanding Treatment Access in Low and Middle Income Countries

Gilead’s dedicated Access team meets with public health officials, doctors and patients around the world to understand barriers and opportunities in HIV, viral hepatitis and visceral leishmaniasis (VL) treatment access.

Read More About Our Access Team

Gilead Sciences and WHO tackle VL in Southeast Asia

Visceral leishmaniasis (VL) is a parasitic disease with an estimated 50,000 to 90,000 new cases worldwide each year, out of which only an estimated 25 to 45% are reported. VL is almost always fatal if untreated. We are collaborating with the World Health Organization (WHO) to provide AmBisome® free of charge to all patients diagnosed with the disease.

Read More About How We’re Helping the WHO Tackle VL

AmBisome bottle with text stating 300,000 vials of AmBisome  are distributed in six countries to treat VL

Statistical graphic representing that 60-70 of every 100 people with Hepatitis C will develop chronic liver disease

Helping eliminate chronic hepatitis C worldwide

WHO is working to eliminate viral hepatitis worldwide by 2030. Through awareness, screening and care, we’re helping governments, patients and payers in efforts to eliminate the chronic hepatitis C virus (HCV) and end the disease.

Read More About The Effort to Eliminate HCV

Italy’s first HIV/HCV support center for LGBT population

BLQ Checkpoint in Bologna, Italy – supported by Gilead – is Italy’s first and only community HIV and HCV testing center. It also offers support, counseling, education and a comfortable environment for members of the LGBT community.

Read More About BLQ Checkpoint

Two men shaking hands

Group of young woman involved in PEPFAR

Keeping girls and young women HIV-free in sub-Saharan countries

Gilead partners with the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) to help reduce HIV infections in adolescent girls and young women in 10 sub-Saharan African countries. The DREAMS program has helped cut new diagnoses by up to 40 percent.

Read More About Our HIV Initiative in sub-Saharan Africa